Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework @Cosmo_Pharma #HealthCare #OTC #OTCMarkets #OTCStocks #Investing
Ad hoc announcement pursuant to Art. 53 LR Full Year 2025 revenue of €104.2 million, in line with guidance, with 85% recurring revenues Recurring revenues of €88.1 million, +15% year-over-year, reflecting structural business transformation EBITDA of €9.5 million, exceeding the upper end of guidance Cash, equivalents and investments of €128.3 million as of December 31, 2025; no financial debt Proposed... http://dlvr.it/TRN753